---
title: "Correction: HBV reactivation risk during lymphoma treatment in HBsAg and HBV DNA double‑negative p"
id: "plos-one-2-correction-risk-of-hepatitis-b-virus-reactivation-in-the-treatment-of-hbsag-and"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-2-correction-risk-of-hepatitis-b-virus-reactivation-in-the-treatment-of-hbsag-and"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0356789"
published_at: "2026-08-20T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Correction: HBV reactivation risk during lymphoma treatment in HBsAg and HBV DNA double‑negative p
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-2-correction-risk-of-hepatitis-b-virus-reactivation-in-the-treatment-of-hbsag-and
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0356789)
- **Published At:** 2026-08-20T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- This is a formal correction to a previously published PLOS One article assessing risk of **hepatitis B virus (HBV) reactivation** in lymphoma patients who were both HBsAg- and HBV DNA–negative at baseline. The publisher identified and corrected presentation and textual errors in the published article. - Table 1 originally contained a redundant percentage sign in the revised data for treatment duration; the corrected table removes the redundant “%” and preserves a single percent symbol in the header. - In the Results subsection of the Abstract, the final sentence was corrected to state that there were no statistically significant differences in HBV reactivation rates by **gender** (P = 0.637, OR = 0.855) or by **treatment duration** (P = 0.837). - In the corrected Results paragraph on treatment duration, patients with treatment duration >30 months were excluded from intergroup comparisons because each group had fewer than 20 patients in that category. - The corrected analysis found no statistically significant difference in HBV reactivation incidence across different treatment-duration groups (P = 0.837). - Reactivation occurred across most treatment-duration intervals except the 24–27 month group, which had no reactivation events reported. - The highest observed frequency of HBV reactivation was 3.41% during the 15–18 month period (based on 3 cases); 14 cases (2.71%) occurred during the 3–6 month period. - The publisher issued an apology for the errors and supplied an updated Table 1 image; the correction references the original research article citation. - The correction document does not add new clinical recommendations or report additional analyses beyond the corrected wording and table adjustments.
## Clinical Analysis & Structured Key Points
[ Skip to main content ](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0356789#main-content) Advertisement * [plos.org](https://plos.org/) * [Create account](https://community.plos.org/registration/new) * [Sign in](https://journals.plos.org/user/secure/login?page=%2Fplosone%2Farticle%3Fid%3D10.1371%2Fjournal.pone.0356789) * * About * Browse * Publish * [](https://journals.plos.org/plosone/ "PLOS One") * Search [advanced search](https://journals.plos.org/plosone/search) * [Browse Topics](https://journals.plos.org/plosone/subjectAreaBrowse) Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click [here](https://github.com/PLOS/plos-thesaurus/blob/master/README.md "Link opens in new window"). [](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0356789) [](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0356789) * 0 [Save](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0356789#savedHeader) [Total Mendeley and Citeulike bookmarks.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0356789#savedHeader) * 0 [Citation](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0356789#citedHeader) [Paper's citation count computed by Dimensions.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0356789#citedHeader) * 18 [View](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0356789#viewedHeader) [PLOS views and downloads.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0356789#viewedHeader) * 0 [Share](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0356789#discussedHeader) [Sum of Facebook, Twitter, Reddit and Wikipedia activity.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0356789#discussedHeader) Open Access Correction # Correction: Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients * The PLOS One Staff # Correction: Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients * The PLOS One Staff ![PLOS](https://journals.plos.org/resource/img/logo-plos-full-color.svg) x * Published: August 20, 2026 * * [Article](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0356789) * [Metrics](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0356789) * [Comments](https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0356789) * [Media Coverage](http://plos.altmetric.com/details/doi/10.1371/journal.pone.0356789) * [Reference](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0356789#reference) * [Reader Comments](https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0356789) * [Figures](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0356789) In Table 1, a percentage sign (%) is already displayed in the header (the first row of the table), and there is a redundant “%” in the newly revised data for duration of treatment. Please see the correct Table 1 here. In the Results subsection of the Abstract, there is an error in the last sentence of the paragraph. The correct sentence is: Conversely, no statistically significant differences in HBV reactivation rates were observed between patients of different genders (P = 0.637, OR = 0.855) or across varying treatment durations (P = 0.837). In the Impact of treatment duration on HBV reactivation subsection of the Results, there are errors in the paragraph. The correct paragraph is: Since patients with a treatment duration exceeding 30 months in each group are fewer than 20, they are excluded from the intergroup comparison of treatment durations. And there was no statistically significant difference in the incidence of HBV reactivation among lymphoma patients who underwent different treatment durations (P = 0.837). Except for patients who did not experience HBV reactivation within the 24–27 months treatment period, HBV reactivation occurred in all other stages. Among those who experienced reactivation, the highest frequency of HBV reactivation (3.41%) was observed during the 15–18 months treatment period, although there were only 3 cases. In contrast, 14 cases (2.71%) of HBV reactivation occurred during the 3–6 months treatment period (Table 1). The publisher apologizes for the errors. [![thumbnail](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0356789.t001)](https://journals.plos.org/plosone/article/figure/image?size=medium&id=10.1371/journal.pone.0356789.t001 "Click for larger image") Download: * [PNG larger image](https://journals.plos.org/plosone/article/figure/image?download&size=large&id=10.1371/journal.pone.0356789.t001) * [TIFF original image](https://journals.plos.org/plosone/article/figure/image?download&size=original&id=10.1371/journal.pone.0356789.t001) Table 1. The results of different factors affecting HBV reactivation. [ https://doi.org/10.1371/journal.pone.0356789.t001](https://doi.org/10.1371/journal.pone.0356789.t001) ## Reference 1. 1. Chen L, Lu Z, Zhang X, Lai J, Huang G, Zheng Y. Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients. PLoS One. 2025;20(9):e0332421. pmid:40961165 * [ View Article ](https://doi.org/10.1371/journal.pone.0332421 "Go to article") * [ PubMed/NCBI ](http://www.ncbi.nlm.nih.gov/pubmed/40961165 "Go to article in PubMed") * [ Google Scholar ](http://scholar.google.com/scholar?q=Risk+of+hepatitis+B+virus+reactivation+in+the+treatment+of+HBsAg+and+HBV+DNA+double-negative+lymphoma+patients+Chen+2025 "Go to article in Google Scholar") ## Figures ![Table 1](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0356789.t001) ![Table 1](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0356789.t001) ![Table 1](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0356789.t001) **Citation:** The _PLOS One_ Staff (2026) Correction: Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients. PLoS One 21(8): e0356789. https://doi.org/10.1371/journal.pone.0356789 **Published:** August 20, 2026 **Copyright:** © 2026 The PLOS One Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. [Download PDF](https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0356789&type=printable) * [Citation](https://journals.plos.org/plosone/article/citation?id=10.1371/journal.pone.0356789) * [XML](https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0356789&type=manuscript) [Print](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0356789) Share * [![Reddit](https://journals.plos.org/resource/img/icon.reddit.16.png)Reddit](https://www.reddit.com/submit?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0356789 "Submit to Reddit") * [![Facebook](https://journals.plos.org/resource/img/icon.fb.16.png)Facebook](https://www.facebook.com/share.php?u=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0356789&t=Correction:%20Risk%20of%20hepatitis%20B%20virus%20reactivation%20in%20the%20treatment%20of%20HBsAg%20and%20HBV%20DNA%20double-negative%20lymphoma%20patients "Share on Facebook") * [![LinkedIn](https://journals.plos.org/resource/img/icon.linkedin.16.png)LinkedIn](https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0356789&title=Correction:%20Risk%20of%20hepatitis%20B%20virus%20reactivation%20in%20the%20treatment%20of%20HBsAg%20and%20HBV%20DNA%20double-negative%20lymphoma%20patients&summary=Checkout%20this%20article%20I%20found%20at%20PLOS "Add to LinkedIn") * [![Mendeley](https://journals.plos.org/resource/img/icon.mendeley.16.png)Mendeley](https://www.mendeley.com/import/?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0356789 "Add to Mendeley") * [![Bluesky](https://journals.plos.org/resource/img/icon.bluesky.light.png)Bluesky](https://bsky.app/intent/compose?text=Checkout%20this%20article%20I%20found%20at%20PLOS:%20https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0356789 "Share on Bluesky") * ![Email](https://journals.plos.org/resource/img/icon.email.16.png)Email ![Check for updates via CrossMark](https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_BW_horizontal.svg) ### Related PLOS Articles * **CORRECTION pertains to** * Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients * [View Page](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0332421) * [PDF](https://journals.plos.org/plosone/article/file?type=printable&id=10.1371/journal.pone.0332421 "PDF opens in new window") Advertisement * [Publications](https://plos.org/our-journals/) * [PLOS Aging and Health](https://journals.plos.org/agingandhealth/) * [PLOS Biology](https://journals.plos.org/plosbiology/) * [PLOS Climate](https://journals.plos.org/climate/) * [PLOS Complex Systems](https://journals.plos.org/complexsystems/) * [PLOS Computational Biology](https://journals.plos.org/ploscompbiol/) * [PLOS Digital Health](https://journals.plos.org/digitalhealth/) * [PLOS Ecosystems](https://journals.plos.org/ecosystems/) * [PLOS Genetics](https://journals.plos.org/plosgenetics/) * [PLOS Global Public Health](https://journals.plos.org/globalpublichealth/) * [PLOS Medicine](https://journals.plos.org/plosmedicine/) * [PLOS Mental Health](https://journals.plos.org/mentalhealth/) * [PLOS Neglected Tropical Diseases](https://journals.plos.org/plosntds/) * [PLOS One](https://journals.plos.org/plosone/) * [PLOS Pathogens](https://journals.plos.org/plospathogens/) * [PLOS Sustainability and Transformation](https://journals.plos.org/sustainabilitytransformation/) * [PLOS Water](https://journals.plos.org/water/) * [Home](https://plos.org) * [Blogs](https://blogs.plos.org) * [Collections](https://collections.plos.org/) * Give feedback * [LOCKSS](https://journals.plos.org/plosone/lockss-manifest) * [Privacy Policy](https://plos.org/privacy-policy) * [Terms of Use](https://plos.org/terms-of-use) * [Advertise](https://plos.org/advertise/) * [Media Inquiries](https://plos.org/media-inquiries) * [Contact](https://plos.org/contact) ![PLOS](https://journals.plos.org/resource/img/logo-plos-footer.png) PLOS is a nonprofit 501(c)(3) corporation, #C2354500, based in California, US ![PLOS Logo](data:image/svg+xml;charset=utf-8;base64,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) ### Cookie Preference Center Our website uses different types of cookies. Optional cookies will only be set with your consent and you may withdraw this consent at any time. Below you can learn more about the types of cookies PLOS uses and register your cookie preferences. Accept All Cookies ### Customize Your Cookie Preference +**Strictly Necessary** Always On +**Functional** OnOff +**Performance and Analytics** OnOff +**Marketing** OnOff Save Selected Preferences and Close [For more information about the cookies and other technologies used by us, please read our Cookie Policy.](https://plos.org/cookies-policy)
## Related Clinical Research

- [Obesity-associated inflammation and cancer: mechanisms linking adipose immune changes to tumor risk](https://medichelpline.com/clinical-feed/frontiers-in-immunology-6-obesity-associated-inflammation-and-cancer-molecular-mechanisms-evidence-gaps.md)
- [Reconciling Genomic Ambiguity and Clinical Certainty in Refractory Panniculitis — Case Report](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-case-report-reconciling-genomic-ambiguity-with-clinical-certainty-in-refractory.md)
- [Erianin and Doxorubicin in Diffuse Large B-Cell Lymphoma: Study Overview on GSDMD, PI3K/AKT, and S](https://medichelpline.com/clinical-feed/pubmed-40830921.md) (DOI: 10.1097/CM9.0000000000003634)
- [Rituximab Maintenance with Ibrutinib-Based Regimens in Younger, Untreated Mantle Cell Lymphoma — T](https://medichelpline.com/clinical-feed/pubmed-42447409.md) (DOI: 10.1200/JCO-26-00705)
- [TSPAN32 boosts CAR‑T efficacy by assembling the IL‑2 receptor and enhancing signaling](https://medichelpline.com/clinical-feed/british-journal-of-cancer-2-tspan32-enhances-car-t-cell-potency-by-assembling-il-2-receptor-complex-and.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.